Impact of comorbidities on outcome with second and further line TKI treatment in patients with chronic myeloid leukemia

Yildirim-Zuemruet G, Kohlbrenner K, Hehlmann R, Fabarius A, Baerlocher GM, Krause S, Burchert A, Hofmann WK, Hochhaus A, Pfirrmann M, Lauseker M, Saussele S (2019)

Publication Type: Conference contribution

Publication year: 2019

Journal

Oncology Research and Treatment Karger Publishers

Publisher: KARGER

City/Town: BASEL

Pages Range: 131-131

Conference Proceedings Title: ONCOLOGY RESEARCH AND TREATMENT

Authors with CRIS profile

Stefan Krause Department of Medicine 5 – Haematology and Oncology

Involved external institutions

Ruprecht-Karls-Universität Heidelberg DE Germany (DE) Inselspital, Universitätsspital Bern CH Switzerland (CH) Universitätsklinikum Gießen und Marburg (UKGM) DE Germany (DE) Universitätsklinikum Jena DE Germany (DE) Ludwig-Maximilians-Universität (LMU) DE Germany (DE)

How to cite

APA:

Yildirim-Zuemruet, G., Kohlbrenner, K., Hehlmann, R., Fabarius, A., Baerlocher, G.M., Krause, S.,... Saussele, S. (2019). Impact of comorbidities on outcome with second and further line TKI treatment in patients with chronic myeloid leukemia. In ONCOLOGY RESEARCH AND TREATMENT (pp. 131-131). BASEL: KARGER.

MLA:

Yildirim-Zuemruet, G., et al. "Impact of comorbidities on outcome with second and further line TKI treatment in patients with chronic myeloid leukemia." Proceedings of the ONCOLOGY RESEARCH AND TREATMENT BASEL: KARGER, 2019. 131-131.

BibTeX: Download